Growth Metrics

Cellectis (CLLS) Revenue (2015 - 2026)

Cellectis (CLLS) posted Revenue of $5.8 million for Q1 2026, down 54.57% on a QoQ basis from $12.7 million in Q4 2025, and down 45.78% year-over-year from $10.7 million in Q1 2025.

Cellectis (CLLS) has 12 years of Revenue data on file, last reported at $5.8 million in Q1 2026.

  • In Q1 2026, Revenue fell 45.78% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $70.4 million (up 27.19% YoY), while the FY2025 annual figure was $72.9 million, up 48.22% from the prior year.
  • Revenue eased to $5.8 million in Q1 2026, from $12.7 million in the prior quarter.
  • Across five years, Revenue topped out at $35.2 million in Q3 2025 and bottomed at $139000.0 in Q1 2023.
  • A 5-year average of $8.8 million and a median of $5.8 million in 2026 frame the typical range for Revenue.
  • Annual changes were most pronounced in 2023 — Revenue sank 98.23% — and 2024, when it soared 10351.61%.
  • Year by year, Revenue stood at $16.0 million in 2022, then sank by 98.23% to $283000.0 in 2023, then surged by 7118.37% to $20.4 million in 2024, then sank by 37.75% to $12.7 million in 2025, then plunged by 54.57% to $5.8 million in 2026.
  • The last three Revenue figures came in at $5.8 million (Q1 2026), $12.7 million (Q4 2025), and $35.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Cellectis 20.83 Bn 20.62 Bn - 5.78 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.78 Mn
Dec 31, 2025 12.72 Mn
Sep 30, 2025 35.17 Mn
Jun 30, 2025 16.73 Mn
Mar 31, 2025 10.66 Mn
Dec 31, 2024 20.43 Mn
Sep 30, 2024 16.20 Mn
Jun 30, 2024 8.06 Mn
Mar 31, 2024 4.53 Mn
Dec 31, 2023 283,000.00
Sep 30, 2023 155,000.00
Jun 30, 2023 178,000.00
Mar 31, 2023 139,000.00
Dec 31, 2022 16.02 Mn
Sep 30, 2022 175,000.00
Jun 30, 2022 1.31 Mn
Mar 31, 2022 1.67 Mn
Dec 31, 2021 10.26 Mn
Sep 30, 2021 8.31 Mn
Jun 30, 2021 11.18 Mn
Mar 31, 2021 25.60 Mn
Dec 31, 2020 13.65 Mn
Sep 30, 2020 6.18 Mn
Jun 30, 2020 2.90 Mn
Mar 31, 2020 50.13 Mn
Dec 31, 2019 4.42 Mn
Sep 30, 2019 8.49 Mn
Jun 30, 2019 1.15 Mn
Mar 31, 2019 1.04 Mn
Dec 31, 2018 968,000.00
Sep 30, 2018 906,000.00
Jun 30, 2018 5.05 Mn
Mar 31, 2018 6.04 Mn
Dec 31, 2017 6.91 Mn
Sep 30, 2017 6.12 Mn
Jun 30, 2017 6.49 Mn
Mar 31, 2017 6.74 Mn
Dec 31, 2016 8.20 Mn
Sep 30, 2016 11.27 Mn
Jun 30, 2016 674,535.39
Mar 31, 2016 7.70 Mn
Dec 31, 2015 36.20 Mn
Sep 30, 2015 8.45 Mn
Jun 30, 2015 8.10 Mn
Mar 31, 2015 9.52 Mn